Centessa Pharmaceuticals (CNTA) Cash from Financing Activities (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Cash from Financing Activities data on file, last reported at $30.5 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $30.5 million, up 887.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $318.9 million (down 10.76% YoY), and the FY2025 annual result was $291.5 million, down 20.08% from the prior year.
• Cash from Financing Activities declined to $30.5 million in Q1 2026 per CNTA's latest filing, from $283.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $283.4 million in Q4 2025 and troughed at $12000.0 in Q2 2023.
• A 5-year average of $44.3 million and a median of $3.3 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 99.98% in 2022, then surged 877508.33% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $89000.0 in 2022, then surged by 7047.19% to $6.4 million in 2023, then sank by 53.42% to $3.0 million in 2024, then soared by 9464.63% to $283.4 million in 2025, then tumbled by 89.25% to $30.5 million in 2026.
• Business Quant data shows CNTA's Cash from Financing Activities at $30.5 million in Q1 2026, $283.4 million in Q4 2025, and $3.4 million in Q3 2025.